Herman H W Sillje
Overview
Explore the profile of Herman H W Sillje including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
5221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voorrips S, Palm C, Saucedo-Orozco H, Mahmoud B, Schouten E, Feringa A, et al.
Eur J Heart Fail
. 2025 Mar;
PMID: 40069113
Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood. We sought to determine...
2.
Li S, Withaar C, Rodrigues P, Zijlstra S, de Boer R, Sillje H, et al.
Biomed Pharmacother
. 2024 Dec;
181:117711.
PMID: 39616735
Heart failure with preserved ejection fraction (HFpEF) is posing a significant medical challenge due to its growing prevalence, high hospitalization rates and limited response to current treatment options. Accumulating evidence...
3.
Foo B, Amedei H, Kaur S, Jaawan S, Boshnakovska A, Gall T, et al.
PLoS One
. 2024 Oct;
19(10):e0311203.
PMID: 39446877
Phospholamban (PLN) is a sarco-endoplasmic reticulum (SER) membrane protein that regulates cardiac contraction/relaxation by reversibly inhibiting the SERCA2a Ca2+-reuptake pump. The R14Δ-PLN mutation causes severe cardiomyopathy that is resistant to...
4.
de Vries H, Eijgenraam T, Bloks V, Mulder N, van Zutphen T, Sillje H, et al.
Pediatr Res
. 2024 Oct;
PMID: 39358409
Background: High plasma bile acids (BAs), for instance due to intrahepatic cholestasis of pregnancy or neonatal cholestasis, are associated with cardiac abnormalities. Here, we exploited the variability in plasma BA...
5.
Stege N, de Boer R, Makarewich C, van der Meer P, Sillje H
JACC Basic Transl Sci
. 2024 Sep;
9(8):1041-1052.
PMID: 39297138
The phospholamban (PLN) pathogenic gene variant, p.Arg14del (PLN-R14del), can lead to dilated and arrhythmogenic cardiomyopathy, resulting in heart failure. PLN-R14del cardiomyopathy has been conceptualized as a disease caused by sarco/endoplasmic...
6.
Wiedemann J, Paruchuru S, den Boef L, Brouwer U, Sillje H, Schouten E, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):191-201.
PMID: 39151832
Purpose: When irradiating thoracic tumors, dose to the heart or lung has been associated with survival. We previously showed in a rat model that in addition to known side effects...
7.
de Wit S, Geerlings L, Shi C, Dronkers J, Schouten E, Blancke G, et al.
Cardiovasc Res
. 2024 Feb;
120(6):612-622.
PMID: 38400709
Aims: Heart failure (HF) and cancer are the leading causes of death worldwide. Epidemiological studies revealed that HF patients are prone to develop cancer. Preclinical studies provided some insights into...
8.
Stege N, Oliveira Nunes Teixeira V, Zijlstra S, Feringa A, de Boer R, Sillje H
Am J Physiol Heart Circ Physiol
. 2024 Feb;
326(3):H870-H876.
PMID: 38334971
The phospholamban () pathogenic gene variant p.Arg14del causes cardiomyopathy, which is characterized by perinuclear PLN protein clustering and can lead to severe heart failure (HF). Elevated expression of dwarf open...
9.
Maniezzi C, Eskandr M, Florindi C, Ferrandi M, Barassi P, Sacco E, et al.
Acta Physiol (Oxf)
. 2024 Jan;
240(3):e14082.
PMID: 38214033
Aims: The heterozygous phospholamban (PLN) mutation R14del (PLN R14del ) is associated with a severe arrhythmogenic cardiomyopathy (ACM) developing in the adult. "Superinhibition" of SERCA2a by PLN R14del is widely...
10.
Withaar C, Meems L, Nollet E, Schouten E, Schroeder M, Knudsen L, et al.
JACC Basic Transl Sci
. 2023 Dec;
8(10):1298-1314.
PMID: 38094687
Obesity-related heart failure with preserved ejection fraction (HFpEF) has become a well-recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may represent a rational treatment strategy. This study investigated semaglutide, a...